Quintin Lai Net Worth

The estimated Net Worth of Quintin J Lai is at least 11.9 百万$ dollars as of 11 August 2023. Quintin Lai owns over 21,101 units of West Pharmaceutical Services stock worth over 11,914,706$ and over the last 6 years he sold WST stock worth over 0$. In addition, he makes 0$ as Vice President - Corporate Development、 Strategy and Investor Relations at West Pharmaceutical Services.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Quintin Lai WST stock SEC Form 4 insiders trading

Quintin has made over 3 trades of the West Pharmaceutical Services stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 21,101 units of WST stock worth 2,646,065$ on 11 August 2023.

The largest trade he's ever made was exercising 21,101 units of West Pharmaceutical Services stock on 11 August 2023 worth over 2,646,065$. On average, Quintin trades about 3,526 units every 64 days since 2019. As of 11 August 2023 he still owns at least 39,407 units of West Pharmaceutical Services stock.

You can see the complete history of Quintin Lai stock trades at the bottom of the page.

Quintin Lai biography

Dr. Quintin J. Lai Ph.D. serves as Vice President - Corporate Development, Strategy and Investor Relations of the Company. Prior to joining West, he was Vice President of Investor Relations and Corporate Strategy at Sigma-Aldrich Corporation from 2012 to 2015. From 2002 to 2012, he was at Robert W. Baird & Company, where he held various roles, including Managing Director and Senior Equity Research Analyst of the Life Science Tools and Diagnostic sector and Associate Director of Equity Research.

How old is Quintin Lai?

Quintin Lai is 53, he's been the Vice President - Corporate Development、 Strategy and Investor Relations of West Pharmaceutical Services since 2016. There are 18 older and 8 younger executives at West Pharmaceutical Services. The oldest executive at West Pharmaceutical Services, Inc. is Patrick Zenner, 73, who is the Independent Chairman of the Board.

What's Quintin Lai's mailing address?

Quintin's mailing address filed with the SEC is , 530 HERMAN O. WEST DRIVE, EXTON, PA, 19341.

Insiders trading at West Pharmaceutical Services

Over the last 19 years, insiders at West Pharmaceutical Services have traded over 32,829,857$ worth of West Pharmaceutical Services stock and bought 19,924 units worth 1,139,950$ . The most active insiders traders include Robert F Friel、Paolo Pucci、Douglas A Michels. On average, West Pharmaceutical Services executives and independent directors trade stock every 40 days with the average trade being worth of 4,786,805$. The most recent stock trade was executed by Charles Witherspoon on 19 August 2024, trading 1,029 units of WST stock currently worth 308,700$.

What does West Pharmaceutical Services do?

west works side-by-side with healthcare partners from concept to the patient, designing and manufacturing packaging and delivery systems that promote efficiency, reliability and safety. west leads the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched knowledge of relevant pharmaceutical product testing, development and packaging. west supports customers from sales, manufacturing, and research and development locations in north and south america, europe, asia and australia.

Complete history of Quintin Lai stock trades at West Pharmaceutical Services

West Pharmaceutical Services executives and stock owners

West Pharmaceutical Services executives and other stock owners filed with the SEC include:

• Eric Green,
  President, Chief Executive Officer, Director
• Eric M. Green,
  Pres, CEO & Director
• Bernard Birkett,
  Chief Financial Officer, Senior Vice President
• George Miller,
  Senior Vice President, General Counsel, Corporate Secretary
• Bernard J. Birkett,
  Sr. VP & CFO
• Silji Abraham,
  Senior Vice President and Chief Digital and Transformation Officer
• David Montecalvo,
  Senior Vice President, Chief Operating and Supply Chain Officer
• Annette Favorite,
  Chief Human Resource Officer, Senior Vice President
• David A. Montecalvo,
  Sr. VP and Chief Operations & Supply Chain Officer
• Silji Abraham,
  Sr. VP & Chief Technology Officer
• Patrick Zenner,
  Independent Chairman of the Board
• Douglas Michels,
  Independent Director
• Thomas Hofmann,
  Independent Director
• Paula Johnson,
  Independent Director
• William Feehery,
  Independent Director
• Mark Buthman,
  Independent Director
• Myla Lai-Goldman,
  Independent Director
• Paolo Pucci,
  Independent Director
• Deborah Keller Tanner,
  Independent Director
• Chad Winters,
  Chief Accounting Officer, Principal Accounting Officer, Vice President, Controller
• Robert Friel,
  Independent Director
• Cindy Reiss-Clark,
  Senior Vice President of Global Market Units and Commercial Solutions
• Quintin Lai,
  Vice President - Corporate Development, Strategy and Investor Relations
• Eric Resnick,
  Chief Technology Officer, Vice President
• Richard D. Luzzi,
  Sr. VP of HR
• Annette F. Favorite,
  Chief HR Officer & Sr. VP
• Michele Polinsky,
  VP of Global Communications
• Kimberly Banks MacKay,
  Sr. VP, Gen. Counsel & Company Sec.
• Dr. Quintin J. Lai C.F.A., Ph.D.,
  VP of Strategy & Investor Relations
• Daniel Malone,
  Vice President & Controller
• William J Federici,
  VP & CFO
• John H Weiland,
  Director
• Karen Flynn,
  President, America's Region
• Heino Lennartz,
  President Europe
• Anthony Welters,
  Director
• Warwick Bedwell,
  VP Pharma Pkgs Systems Asia Pa
• John E Paproski,
  Vice President-Innovations
• Christopher G Ryan,
  President, PPS, Americas
• Rachael M Bushey,
  VP, Deputy Gen Coun & Corp Sec
• Jeffrey C Hunt,
  VP Pharma Pckg Systems
• John R Gailey,
  VP, Gen. Counsel & Sec.
• Richard D Luzzi,
  VP, Human Resourses
• L Robert Johnson,
  Director
• Michael A Anderson,
  Vice President & Treasurer
• Donald E Jr Morel,
  Chairman of the Board & CEO
• Robert C Young,
  Director
• Donald A Mc Millan,
  President Pharma Systems NA
• Steven A Ellers,
  Pres., Pharma. Systems Div.
• Geoffrey F Worden,
  Director
• John P Neafsey,
  Director
• Joseph E Abbott,
  Corporate Controller
• Dijk Ronald Van,
  President Asia Pacific
• Robert S Hargesheimer,
  President-The Tech Group
• Fabio De Sampaio Doria Filho,
  Pres., Europe & Asia Pacific
• Matthew T Mullarkey,
  Chief Operating Officer
• Robert J Keating,
  Pres., Europe & Asia Pacific
• Jenne K Britell,
  Director
• Herbert L Hugill,
  Pres. of the Americas, Pharma.
• Linda R Altemus,
  VP & Chief Compliance Officer
• Molly Joseph,
  Director
• Deborah L Keller,
  Director
• Stephen H Lockhart,
  Director
• Charles Witherspoon,
  VP & Treasurer
• Kimberly Banks Mac Kay,
  SVP, GC & Corporate Secretary